eGlint Selected for the 2026 BioTools Innovator Cohort

Last week, the eGlint team participated in the 2026 Innovator Summit in San Francisco after being selected into the 2026 BioTools Innovator cohort. The invitation-only event brought together founders, executives, investors, industry leaders, strategic partners, and fellow innovators working to advance the next generation of life science and healthcare technologies.

One message came through consistently throughout the week: stay relentlessly focused on solving real customer problems and creating a clear path to adoption and revenue. This reinforced a direction eGlint has already been pursuing. While our ProteoNex™ platform has the potential to enable a broad range of applications, our near-term focus remains clear: helping pharmaceutical and biotechnology customers replace slow, labor-intensive ELISA workflows with rapid, multiplex protein analysis. This represents a large and well-established market with a significant unmet need, and we believe it provides a capital-efficient beachhead for delivering customer value while continuing to advance the broader platform.

We thank the BioTools Innovator team, mentors, partners, investors, and fellow cohort companies for an outstanding experience. The program provided valuable opportunities to exchange ideas, challenge assumptions, and learn from some of the most accomplished leaders across the life science tools ecosystem.

We are grateful for the continued support of our team, advisors, investors, collaborators, and partners who help make eGlint's mission and progress possible. We look forward to applying these lessons as we continue advancing the ProteoNex™ platform and executing on our commercialization strategy.